Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Focusing on short term investment goals can yield quick financial returns. Discover the right timing for your investment strategy.
27,474 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
As collections on federal student loans restart, Gen Z is bearing the cost with rising delinquencies and falling cred...
Micron Technology rides a surge in AI memory demand, delivering stronger margins and robust cash flow. As the company...
A security flaw allowed a hacker to drain approximately $5.9 million from TrustedVolumes, a DeFi liquidity provider o...
A suburban district is debating whether to curb or ban classroom devices as a growing number of parents push back aga...
In a move that stirs controversy, a $1.7 billion fund is being created to compensate allies in a settlement tied to T...
A Minnesota nonprofit leader was sentenced to nearly 42 years for orchestrating a $250 million fraud tied to pandemic...
The insurance backdrop is stabilizing in mid-2026, but homeowners coverage costs stay stubbornly high. Builders and l...
Israel expanded its Lebanon assault, widening ground incursions as Hezbollah escalates strikes. The move rattles mark...
C3.AI topped Q4 expectations and provided FY27 guidance, sending shares higher after hours as investors weigh the com...
Geopolitical tension in the Middle East sparked a swift crypto reaction, with Bitcoin swinging as officials weigh a p...
A House committee hearing on digital asset taxation highlighted sharp divides among lawmakers on urgency and approach...